Remedium Life — 360° view

Remedium Life, a company in the Trading & Distributors industry, reported revenue of ₹111 crore and net profit of ₹8.62 crore for the September 2025 quarter.

Remedium Life (BSE: SUPHA) closed at ₹0.25 on 20 Nov 2026, down 80.9% over the past year. Its market capitalisation is ₹22 crore and it trades at 10.4 times earnings.

Share price
₹0.25 (20 Nov 2026)
Market cap
₹22 Cr (20 Nov 2026)
P/E
10.36 (20 Nov 2026)
Revenue
₹111 Cr (September 2025 quarter)
Net profit
₹9 Cr (September 2025 quarter)
ROCE
% (FY25)
ROE
4.85% (FY25)
Book value
₹1.19 (FY25)
Dividend yield
0.00% (FY25)
52-week high / low
₹1.34 / ₹0.23 (20 Nov 2026)
1-year return
-80.9% (to 20 Nov 2026)
Sector
Services
Industry
Trading & Distributors
Symbol
BSE: SUPHA

Supha Pharmachem Ltd, formerly Remedium Lifecare, is a pharmaceutical supply-chain trader of APIs, advanced intermediates, KSMs/CRMs and other pharma chemicals for domestic and export markets. It operates through the Indian parent and Singapore subsidiary Remlife Global Pte Ltd and entered CIRP on March 17, 2026.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.